Terazosin how supplied storage and handling: Difference between revisions
(Created page with "__NOTOC__ {{Terazosin}} {{CMG}}; {{AE}} {{AK}} <ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = TERAZOSIN HYDROCHLORIDE CAPSULE [CARDINAL HEAL...") |
No edit summary |
||
| Line 3: | Line 3: | ||
{{CMG}}; {{AE}} {{AK}} | {{CMG}}; {{AE}} {{AK}} | ||
==HOW SUPPLIED== | |||
Terazosin Hydrochloride Capsules are available as: | |||
'''1 mg:''' White capsules imprinted GG 621 in black ink, filled with white powder are supplied as follows: | |||
NDC 0904-6126-61 blister pack of 100 capsules | |||
'''2 mg:''' Yellow capsules imprinted GG 622 in black ink, filled with white powder are supplied as follows: | |||
NDC 0904-6127-61 blister pack of 100 capsules | |||
'''5 mg:''' Pink capsules imprinted GG 623 in black ink, filled with white powder are supplied as follows: | |||
NDC 0904-6128-61 blister pack of 100 capsules | |||
'''10 mg:''' Aqua capsules imprinted GG 624 in black ink, filled with white powder are supplied as follows: | |||
NDC 0904-6125-61 blister pack of 100 capsules | |||
Store at 20°-25°C (68°-77°F) (see USP Controlled Room Temperature). Protect from light and moisture. | |||
Dispense in a tight, light-resistant container.<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = TERAZOSIN HYDROCHLORIDE CAPSULE [CARDINAL HEALTH] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=30503dfd-03bd-46d8-8170-d9ed096fd71d | publisher = | date = | accessdate = 7 March 2014 }}</ref> | |||
==References== | ==References== | ||
Revision as of 03:21, 7 March 2014
| Terazosin |
|---|
| Terazosin®, Hytrin® FDA Package Insert |
| Indications and Usage |
| Dosage and Administration |
| Contraindications |
| Warnings |
| Precautions |
| Adverse Reactions |
| Drug Interactions |
| Use in Specific Populations |
| Overdosage |
| Description |
| Clinical Pharmacology |
| Nonclinical Toxicology |
| How Supplied/Storage and Handling |
| Patient Counseling Information |
| Labels and Packages |
| Clinical Trials on Terazosin |
| ClinicalTrials.gov |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Abdurahman Khalil, M.D. [2]
HOW SUPPLIED
Terazosin Hydrochloride Capsules are available as:
1 mg: White capsules imprinted GG 621 in black ink, filled with white powder are supplied as follows:
NDC 0904-6126-61 blister pack of 100 capsules
2 mg: Yellow capsules imprinted GG 622 in black ink, filled with white powder are supplied as follows:
NDC 0904-6127-61 blister pack of 100 capsules
5 mg: Pink capsules imprinted GG 623 in black ink, filled with white powder are supplied as follows:
NDC 0904-6128-61 blister pack of 100 capsules
10 mg: Aqua capsules imprinted GG 624 in black ink, filled with white powder are supplied as follows:
NDC 0904-6125-61 blister pack of 100 capsules
Store at 20°-25°C (68°-77°F) (see USP Controlled Room Temperature). Protect from light and moisture.
Dispense in a tight, light-resistant container.[1]
References
- ↑ "TERAZOSIN HYDROCHLORIDE CAPSULE [CARDINAL HEALTH]". Retrieved 7 March 2014.